Applied Biosystems maintained by Merrill at neutral

Applied Biosystems was maintained by Merrill Lynch analyst J. Darryl Pardi at a neutral rating after the company announced it would transfer its 50% ownership of Celera Diagnostics to Celera Genomics in exchange for $30 million in cash and other - more valuable - considerations. The reorganization would make it easier for Celera and Applied to separate by reducing the relationship between the two companies and making Celera a more attractive independent asset, Merrill said. Shares of the Foster City, Calif., scientific and technical instruments company were up 94 cents, or 3.49%, at $27.91 on volume of 1,472,500 shares versus the three-month running average of 1,287,980 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.